Natera (NTRA)

• Market cap: $19.9B
• 1 day: -3.50%
• 5 days: -5.37%
• 1 month: -3.08%
• 3 months: -4.16%
• 6 months: 33.14%
• Year to date: 1.06%
• 1 year: 132.67%
• 5 years: 337.38%
• 10 years: 613.76%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Employees: 3,293

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

286% more first-time investments, than exits

New positions opened: 135 | Existing positions closed: 35

24% more capital invested

Capital invested by funds: $15.9B [Q3] → $19.7B (+$3.86B) [Q4]

17% more funds holding

Funds holding: 487 [Q3] → 569 (+82) [Q4]

17% more funds holding in top 10

Funds holding in top 10: 24 [Q3] → 28 (+4) [Q4]

6.64% less ownership

Funds ownership: 100.96% [Q3] → 94.32% (-6.64%) [Q4]

12% less repeat investments, than reductions

Existing positions increased: 179 | Existing positions reduced: 203

17% less call options, than puts

Call options by funds: $136M | Put options by funds: $163M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $180 11% upside
• Avg. target: $195 20% upside
• High target: $200 23% upside

6 analyst ratings

• positive: 6 100%
• neutral: 0 0%
• negative: 0 0%

Goldman Sachs Matthew Sykes 56% 1-year accuracy 22 / 39 met price target	17% upside $190	Buy Maintained	28 Jan 2025
Barclays Luke Sergott 31% 1-year accuracy 16 / 52 met price target	23% upside $200	Overweight Initiated	23 Jan 2025
Guggenheim Subbu Nambi 50% 1-year accuracy 6 / 12 met price target	23% upside $200	Buy Maintained	17 Jan 2025
Bernstein Eve Burstein 57% 1-year accuracy 4 / 7 met price target	23% upside $200	Outperform Maintained	10 Jan 2025
Canaccord Genuity Kyle Mikson 46% 1-year accuracy 13 / 28 met price target	11% upside $180	Buy Maintained	3 Jan 2025